跳至主要内容
临床试验/NCT02649920
NCT02649920终止不适用

Pilot, Comparative, Not Randomized, Two Centers Study Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²)

Centre Hospitalier Departemental Vendee2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2016年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
2
试验地点
2
主要终点
Bishop Score After 24 Hours of Maturation

研究概览

简要总结

At the moment in France, one delivery on four is induced for a medical indication. In this context, the practitioners are exposed to an additional difficulty when the clinical examination of the patient reveals a unfavorable cervix because the main drug used for the releases cannot be used and the cervix must be previously mature.

There is a pharmacological method used and estimated in these indications of cervical maturation: the dinoprostone (Propess®).

Other methods using a mechanical process, are under development and of evaluation as it is the case of the probe of dilation with double balloon (Cook®).

The population of the obese women is a population in constant increase in France and presenting deliveries to higher risks of maternal and foetal complications. At these patients, the medicinal releases seem also more difficult and at greater risks of failures.

The investigators wish compared the efficiency of the cervical ripening balloon to the dinoprostone within the framework of a medical indication in a release with a unfavorable cervix in obese pregnant women.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Age ≥ 18 years
  • •Term ≥ 37 weeks of amenorrhea
  • •Singleton pregnancy
  • •Cephalic presentation
  • •Medical indication of release and unfavorable cervix (Bishop <6)
  • •BM pre-pregnancy ≥ 30 kg/m2
  • •Having given their agreement for the participation of the study
  • •Patient receiving social coverage

排除标准

  • •Age < 18 years
  • •Term < 37 weeks of amenorrhea
  • •Multiple pregnancy
  • •Favorable cervix (Bishop ≥ 6)
  • •Contraindication of vaginal delivery: praevia placenta, transverse presentation, cord prolapse
  • •Evolutive urinary tract infection (positive urine dip: leukocytes/ nitrites)
  • •Not affiliated with a legal protection regime
  • •Patient trust, guardianship, under legal protection measure, deprived of freedom
  • •Balloon's contraindications:
  • •Abnormal pelvis structure
  • •Evolutive genital herpes
  • •Invasive cervical cancer
  • •Anomaly of foetal heart rate
  • •Breech presentation
  • •Maternal heart disorder
  • •Hydramnios
  • •Serious and uncontrolled arterial high blood pressure
  • •Rupture of membranes
  • •Medical histories of hysterotomy, classic uterine section, myomectomy or quite different uterine section of full thickness
  • •Presentation above superior pelvic strait
  • •Dinoprostone's contraindications:
  • •Scarred uterus
  • •Prostaglandin's hypersensitivity

研究组 & 干预措施

Cervical ripening balloon

Experimental

Prospective

干预措施: Cervical ripening balloon (Device)

Dinoprostone

Active Comparator

Retrospective

干预措施: Dinoprostone (Drug)

结局指标

主要结局

Bishop Score After 24 Hours of Maturation

时间窗: 24 hours

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
4 期
Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)Volume OverloadAcute Decompensated Heart Failure
NCT03505788Ziekenhuis Oost-Limburg519
进行中(未招募)
1 期
An open clinical study to evaluate two inhaled treatments containing bronchodilators and cosrticosteroids on the market in terms of effects on some parts of the lungs in patients with chronic obstructive pulmonary disease through a user friendly innovative deviceChronic Obstructive Pulmonary Disease (COPD)
EUCTR2019-002744-24-GBChiesi Farmaceutici S.p.A.36
进行中(未招募)
1 期
A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules. - TRUST study: Raptiva ® in hands & foot psoriasisSubject with chronic (disease history of at least 6 months from diagnosis) moderate to severe plaque psoriasis involving the hands and/or feet (PGA – H&F ratings of 3 or 4) at screening, who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA.MedDRA version: 9.1Level: LLTClassification code 10037153Term: Psoriasis
EUCTR2007-004227-37-FRMerck Serono International SA
进行中(未招募)
不适用
A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules. - TRUST study: Raptiva ® in hands & foot psoriasisSubject with chronic (disease history of at least 6 months from diagnosis) moderate to severe plaque psoriasis involving the hands and/or feet (PGA – H&F ratings of 3 or 4) at screening, who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA.MedDRA version: 9.1Level: LLTClassification code 10037153Term: Psoriasis
EUCTR2007-004227-37-GRMerck Serono International SA168
进行中(未招募)
不适用
A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules. - TRUST study: Raptiva ® in hands & foot psoriasisSubject with chronic (disease history of at least 6 months from diagnosis) moderate to severe plaque psoriasis involving the hands and/or feet (PGA – H&F ratings of 3 or 4) at screening, who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA.MedDRA version: 9.1Level: LLTClassification code 10037153Term: Psoriasis
EUCTR2007-004227-37-DEMerck Serono S.A. - Geneva168